Kathy Davy

Kathy Davy, MBA

President, Clinical Next-Generation Sequencing, Thermo Fisher Scientific

Latest Stories
Guest Editorial
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login